COST EFFECTIVENESS OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR ATRIAL FIBRILLATION IN GUATEMALA

被引：1
|
作者：
Garita, M. [1 ]
Peralta, M. [1 ]
Gordillo, D., I [2 ]
机构：
[1] Pfizer Cent Amer & Caribbean, San Jose, Costa Rica
[2] Hosp Univ Esperanza, Guatemala City, Guatemala
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.671
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV77
引用
收藏
页码：A115 / A115
页数：1
相关论文
共 50 条
  • [1] Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
    Harrington, Amanda R.
    Armstrong, Edward P.
    Nolan, Paul E., Jr.
    Malone, Daniel C.
    [J]. STROKE, 2013, 44 (06) : 1676 - +
  • [2] Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
    Yao, Xiaoxi
    Abraham, Neena S.
    Sangaralingham, Lindsey R.
    Bellolio, M. Fernanda
    McBane, Robert D.
    Shah, Nilay D.
    Noseworthy, Peter A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2016, 5 (06):
  • [3] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Chieh-Yu Liu
    Hui-Chun Chen
    [J]. Clinical Drug Investigation, 2017, 37 : 285 - 293
  • [4] Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan
    Liu, Chieh-Yu
    Chen, Hui-Chun
    [J]. CLINICAL DRUG INVESTIGATION, 2017, 37 (03) : 285 - 293
  • [5] Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation
    Hernandez, Inmaculada
    Zhang, Yuting
    Saba, Samir
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (10): : 1813 - 1819
  • [6] Comparative Effectiveness of Dabigatran, Rivaroxaban, Apixaban, and Warfarin in the Management of Patients With Nonvalvular Atrial Fibrillation
    Pink, J.
    Pirmohamed, M.
    Hughes, D. A.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 94 (02) : 269 - 276
  • [7] COST-EFFECTIVENESS OF EDOXABAN, APIXABAN, RIVAROXABAN AND DABIGATRAN VERSUS WARFARIN FOR STROKE PREVENTION IN NONVALVULAR ATRIAL FIBRILLATION
    Marchetti, M.
    Liberato, N. L.
    Rognoni, C.
    Quaglini, S.
    [J]. HAEMATOLOGICA, 2014, 99 : 487 - 487
  • [8] COST EFFECTIVENESS EVALUATION OF APIXABAN, DABIGATRAN RIVAROXABAN AND WARFARIN FOR PREVENTION OF TROMBOEMBOLISM IN PATIENTS WITH ATRIAL FIBRILLATION IN TRINIDAD AND TOBAGO
    Garita, M.
    Peralta, M.
    Dookie, T. A.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A116 - A117
  • [9] Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
    Martinez, Brandon K.
    Sood, Nitesh A.
    Bunz, Thomas J.
    Coleman, Craig I.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2018, 7 (08):
  • [10] EFFECTIVENESS AND SAFETY OF APIXABAN, DABIGATRAN AND RIVAROXABAN VERSUS WARFARIN IN FRAIL PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
    Coleman, Craig I.
    Turpie, Alexander
    Bunz, Thomas J.
    Sood, Nitesh
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 290 - 290
12345